NCT02434484View on ClinicalTrials.gov

Symbenda Post-Marketing Surveillance (PMS)

CompletedOBSERVATIONAL
Enrollment

84

Participants

Timeline

Start Date

July 4, 2018

Primary Completion Date

March 20, 2020

Study Completion Date

March 20, 2020

Conditions
Lymphoma, Non-HodgkinLymphocytic LeukemiaMultiple Myeloma
Trial Locations (9)

Unknown

Eisai Trial Site #7, Busan

Eisai Trial Site #8, Busan

Eisai Trial Site #6, Daegu

Eisai Trial Site #4, Daejeon

Eisai Trial Site #5, Daejeon

Eisai Trial Site #9, Incheon

Eisai Trial Site #1, Seoul

Eisai Trial Site #2, Seoul

Eisai Trial Site #3, Seoul

All Listed Sponsors
lead

Eisai Korea Inc.

INDUSTRY

NCT02434484 - Symbenda Post-Marketing Surveillance (PMS) | Biotech Hunter | Biotech Hunter